BPA
VRTX icon

Beacon Pointe Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Beacon Pointe Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.47M Sell
17,047
-847
-5% -$375K 0.04% 387
2026
Q1 		$7.99M Buy
17,894
+4,392
+33% +$2.05M 0.04% 367
2025
Q4 		$6.12M Buy
13,502
+218
+2% +$94K 0.04% 340
2025
Q3 		$5.2M Sell
13,284
-2,745
-17% -$1.15M 0.04% 339
2025
Q2 		$7.14M Sell
16,029
-196
-1% -$90.3K 0.07% 237
2025
Q1 		$7.87M Buy
16,225
+22
+0.1% +$10.3K 0.09% 210
2024
Q4 		$6.52M Sell
16,203
-793
-5% -$368K 0.07% 222
2024
Q3 		$7.9M Sell
16,996
-2,185
-11% -$1.05M 0.09% 193
2024
Q2 		$8.99M Sell
19,181
-8
-0% -$3.47K 0.11% 175
2024
Q1 		$8.02M Sell
19,189
-75
-0.4% -$31.7K 0.09% 204
2023
Q4 		$7.84M Sell
19,264
-813
-4% -$300K 0.09% 191
2023
Q3 		$6.98M Buy
20,077
+724
+4% +$253K 0.09% 209
2023
Q2 		$6.81M Sell
19,353
-1,753
-8% -$591K 0.11% 172
2023
Q1 		$6.65M Sell
21,106
-5,230
-20% -$1.57M 0.11% 176
2022
Q4 		$7.61M Sell
26,336
-546
-2% -$166K 0.15% 140
2022
Q3 		$7.79M Sell
26,882
-297
-1% -$85.5K 0.17% 132
2022
Q2 		$7.66M Sell
27,179
-753
-3% -$202K 0.16% 137
2022
Q1 		$7.29M Buy
27,932
+5,414
+24% +$1.28M 0.1% 195
2021
Q4 		$4.95M Sell
22,518
-6,314
-22% -$1.23M 0.13% 145
2021
Q3 		$5.23M Buy
28,832
+17,845
+162% +$3.48M 0.13% 167
2021
Q2 		$2.21M Buy
10,987
+9,536
+657% +$1.99M 0.08% 203
2021
Q1 		$313K Buy
1,451
+70
+5% +$15.4K 0.02% 379
2020
Q4 		$327K Sell
1,381
-183
-12% -$42K 0.02% 350
2020
Q3 		$426K Buy
1,564
+162
+12% +$44.7K 0.04% 246
2020
Q2 		$408K Buy
1,402
+13
+0.9% +$3.52K 0.04% 263
2020
Q1 		$329K Buy
+1,389
New +$319K 0.05% 224

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Beacon Pointe Advisors's VRTX Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q2 2026, selling an estimated $375K and leaving 17,047 shares worth $8.47M. The position accounts for 0.04% of the portfolio, ranked #387.

Beacon Pointe Advisors first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.99M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Beacon Pointe Advisors held 17,047 shares of Vertex Pharmaceuticals worth $8.47M as of Q2 2026.
  • Beacon Pointe Advisors sold 847 Vertex Pharmaceuticals shares in Q2 2026, an estimated $375K.
  • Vertex Pharmaceuticals made up 0.04% of Beacon Pointe Advisors's portfolio in Q2 2026, its #387 holding.
  • Beacon Pointe Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Beacon Pointe Advisors's Vertex Pharmaceuticals position peaked at $8.99M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.